STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 6, 2026, 04:13 PM

Lifevantage Q3 Revenue $43.7M, Net Income $1.36M, EPS $0.11

AI Summary

Lifevantage Corp reported a significant decline in its third-quarter and nine-month financial results for fiscal year 2026. For the three months ended March 31, 2026, net revenue decreased to $43.7 million and net income fell to $1.36 million, with diluted EPS at $0.11. The company also saw a decrease in cash and cash equivalents and net cash provided by operating activities compared to the prior year, alongside a notable increase in inventory obsolescence allowance.

Key Highlights

  • Q3 2026 net revenue decreased to $43.7 million from $58.4 million in Q3 2025.
  • Q3 2026 net income decreased to $1.36 million from $3.47 million in Q3 2025.
  • Q3 2026 diluted EPS was $0.11, down from $0.26 in Q3 2025.
  • Nine-month 2026 net revenue decreased to $140.2 million from $173.4 million in 2025.
  • Nine-month 2026 net income decreased to $3.79 million from $7.85 million in 2025.
  • Cash and cash equivalents decreased to $12.48 million as of March 31, 2026, from $20.20 million at June 30, 2025.
  • Net cash provided by operating activities for nine months decreased to $5.47 million from $10.84 million.
  • Inventory obsolescence allowance increased to $3.1 million at March 31, 2026, from $0.5 million at June 30, 2025.
LFVN
Biotechnology: Pharmaceutical Preparations
Lifevantage Corp

Price Impact